Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Karinca, Thank you for keeping everyone up to date to this point.
Thank you for assemblng that list of new customers and the dates.
It would be satisfying to step on some of those cockroaches. Barry Honig has the right to try to protect his reputation and CDXC deserves a chance to bring it's products to market.
So it appears we have renamed NanoAntibiotis as BioVie, unanimously, by 68 million votes to zero. Guess that's why I wasn't sent a proxy. Not that I would have objected.
The full 8K is above with what was approved.
We shall see, eventually. Go $ROX
Fun, I'll take any obsolete inventory they want to send me.
FUN, When I was in Bermuda last month, it seemed that almost all commerce was conducted in US dollars. Give a $20 US bill for a $10 item and you received a US $10 in change.
Another piece on bees:
http://www.atlasobscura.com/articles/the-case-against-honeybees
Gov, I'm not sure I can parse anything meaningful from this listing.
govorchin Monday, 07/11/16 12:34:17 PM
the following appears in slide show on CTIX website:
Title
Leo Ehrlich, CPA
Chief Executive Officer, Chief Financial Officer
Co-Founder, Cellceutix; Investor
Krishna Menon, PhD, DVM
Chief Scientific Officer
Co-Founder, Cellceutix
Arthur P. Bertolino, MD, PhD, MBA
President, Chief Medical Officer
my question is - coupled with menon's son not listed as a 5% owner on nano antibiotics and menon not listed as an investor on the above and ehrlich is, is it significant?
Yes. Would love to have progressively greater positive news from MARA.
No issues at Fidelity in Buying shares of MARA
I would be surprised if there were not more Form 4 purchases. Go $ROX
$ROX rocks!
JP, I plan to hold as well. I have high hopes (good thing this isn't a marijuana stock) that with this new ascites program and a vigorous, experienced management team, we may start getting somewhere. GLTAL
BigCat, As a holder for over two years, I am happy to have any positive coverage of NNAB. That said, it should be noted that the site on which the report was published is generally paid to do so. As they say in the disclaimer on their site:
"We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained in our reports is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing. Please note that our writers, analysts and site administrators all reserve the right, without prior notice, to sell, buy, cover, liquidate, increase or decrease any positions disclosed in any of the securities covered or written about on this news portal at any time, for any reason. BioMedReport.Com's directors, officers and employees may anticipate purchasing shares mentioned in this report or may already have purchased shares and may profit in the event those shares rise in value. We reserve the right to buy or sell the shares of any companies mentioned in any reports or materials published on this portal at any time.
BioMedReports is committed to providing our readers with useful information on publicly traded companies. Affilitated and parent companies or authors sometimes contract with third parties or publicly traded companies and receives compensation from them in the form of cash and sometimes restricted securities as payment for selling advertisementsa, data, sharing analytics information, distributing information to the investment community via various electronic means and/or including publishing information and opinions about the company and the trading market for their securities. Principals and authors may also purchase or sell securities of the companies in the open market from time to time. The positions that theese affiliated firms or principals maintain in securities of the companies should be considered when making an investment decision regarding companies mentioned on BioMedReports. BioMedReports or affiliated companies may be deemed to have a conflict of interest between its open market activity and positions in these securities and the timing of and opinions expressed in its publications concerning these companies. The publications should not be considered to be independent publications concerning the company.
Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.
We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable."
New press release:
BEVERLY, MA--(Marketwired - July 07, 2016) - NanoAntibiotics, Inc. (OTC PINK: NNAB) (the "Company," soon to be known as BioVie Inc.), a development stage company focused on the discovery, development, and commercialization of innovative drug therapies, announced today the filing of US, Japanese and international (PCT) patent applications. The applications aim to achieve patent protection for the Company's novel CIPT Technology being developed for the treatment of ascites due to liver cirrhosis. The PCT filing is an important step towards safeguarding the technology in Europe and potentially other countries.
The FDA has never approved any drugs specifically for the treatment of ascites, and CIPT Technology offers the potential for a new therapeutic option for patients with this life-threatening condition. "This is an important component of our plan to develop a unique and proprietary new therapy for ascites, and ultimately improve patient care at home and abroad," commented Jonathan Adams, CEO of the Company.
The Company collaborated with its Italian advisor, Professor Paolo Angeli of the University of Padova, to generate data supporting the patent claims. Dr. Angeli is Head of the Unit of Hepatic Emergencies and Liver Transplantation at the University, and is a frequent speaker and widely published expert on liver disease. Penny Markham PhD, the Company's Chief Scientific Officer, also made important contributions to the applications.
NanoAntibiotics (BioVie) recently launched a new website, www.nanoantibiotics.com. The Company's goal is to commence a clinical trial program as early as 2017 upon FDA acceptance of an Investigational New Drug ("IND") application, currently in development.
About Liver Cirrhosis and Ascites
About 1 million Americans and millions worldwide suffer from liver cirrhosis. Cirrhosis is the 12th leading cause of death due to disease in the US, killing an estimated 27,000 people each year. The condition results primarily from hepatitis, alcoholism, and fatty liver disease linked to obesity. Ascites is a common complication of advanced liver cirrhosis, involving kidney dysfunction and the accumulation of large amounts of fluid in the abdominal cavity. With no medications approved by the FDA specifically for treating ascites, an estimated 40% of patients die within two years of diagnosis. Certain drugs approved for other uses may provide initial relief, but patients may fail to respond to treatment as ascites worsens. This represents a critical unmet medical need. US treatment costs for liver cirrhosis, including ascites and other complications, are estimated at more than $4 billion annually.
About NanoAntibiotics (BioVie)
NanoAntibiotics, Inc. (soon to be known as BioVie Inc.) is a development stage company pursuing the discovery, development, and commercialization of innovative drug therapies. The Company is currently focused on commercializing CIPT Technology, a novel approach to the treatment of ascites due to liver cirrhosis. In early 2016 the Company held a pre-investigational new drug ("pre-IND") meeting with the FDA, which provided guidance for an IND submission. The Company's new drug candidate could potentially commence US clinical trials as early as 2017.
Forward-Looking Statements
The Company's patent applications are subject to regulatory risks and may never be approved. This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause NanoAntibiotics' actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. NanoAntibiotics has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are NanoAntibiotics' need for, and the availability of, substantial capital in the future to fund its operations and research and development. The fact that NanoAntibiotics' compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in NanoAntibiotics' filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. NanoAntibiotics undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
Copyright © 2016 NanoAntibiotics, Inc., All rights reserved.
Thanks for subscribing to our alerts!
Our mailing address is:
NanoAntibiotics, Inc.
9511 collins avenue #807
Surfside, FL 33154
Hyr, You might look at Fidelity. $7.95, no matter how many shares.
They are the ones!
tres cool
Article on Google's lack of transparency on it's patents.
http://cpip.gmu.edu/2016/06/30/do-as-i-say-not-as-i-do-googles-patent-transparency-hypocrisy/
All pretty much on the mark! The video, and tripadvisor review were accurate.
Fun, Still don't have everything together but here goes.
Wife, kid, M-I-L and I booked passage on the Goslings Rum Sunset Cruise for while we were in Bermuda.
The rum cruise was great. Ship docked in Dockyards. Rum Cruise left the dock, just a short walk away from our ship, about 45 minutes before sunset. Sailed around the northern end of Dockyards to watch the sunset and hear stories about the founding of Goslings, the Maytag washing machine, etc. Got some great pix.
Had all sorts of straight Goslings this or that, plus all sorts of combinations. Got totally blasted, as my MIL was passing me at least half of her drinks and my wife gave me some of hers and the people going around willingly topped off my glasses. The kid held her own. Only problem was that my wife had a cold and kept switching my cup for hers. We'll see if I fought it off, thanks to all the alcohol "disinfectant."
Prices from their duty-free shop were better than those here, but not so much better as to justify dragging all that weight home. However, I brought home a couple bottles of Goslings Bermuda Gold Liqueur, not sold here - supposedly.
Only bummer was that, had we fully understood the credits on NCL toward shore excursions, we would have understood that $150 credit was really $50/day credit and not wasted some of it. Hell, I could have gone on the Goslings Rum Sunset Cruise TWICE, had I known that.
Just,
The 75mg Niagen CVS product, to which Karinca referred, was discontinued, marked down 75 percent (to $4.94 for 60 capsules, which was a good deal for the consumer) and is now off the shelves of all my local CVS stores. They appeared to only have three or four bottles per store. I wish you and anyone else well if you find them.
As Karinca noted, it is really a small dose in those capsules, and I noticed no effect at all until I got up to three capsules (215mg) at a time.
I hope CVS will at least introduce one of the labels which contains NR in a larger dose. GLTU
Agree with all you said. I am familiar with the attacks by these authors and Rosen on CTI*, which is my largest holding. They (minus Mr. Bleak street) also attacked MNO*, another stock I hold, with less success. They give pond scum a good name by comparison with themselves.
Good, we agree then. It was good to post it.
Long CDXC since 30 cents pre-r/s
Just,
While I take Niagen and pterostylbene and agree with at least some of the findings you mentioned from that site (and I might believe in all of it but have not YET confirmed from my own usage), you should point out that the site sells Niagen.
It's not as if they are a scientific site, doing disinterested studies. People should read the scientific papers to confirm that the site has presented the results fairly.
All just IMHO, no offense intended.
Karin, Good first article on CDXC. Hope to see many more.
Yes, not too much actual facts to build on here...yet. Will be interesting to watch.
Interesting how Ehrlich junior retained shares while Menon junior did not. At least not to the level of a five percent shareholder. No other Ehrlichs or Menons shown at that level.
The proxy solicitation now shows major shareholders. Apologies for the formatting.
http://archive.fast-edgar.com//20160620/A322822CN222I2Z22229223ZGNMGP2H2H282/
"The table also shows the number of shares beneficially owned as of June 6, 2016 by each of the individual directors and executive officers and by all directors and executive officers as a group.
Name of Beneficial Owner Title of Class
Beneficial
Ownership(1)
Percent of
Class(2)
Jonathan Adams Common Stock 6,168,066 7.1 %
Amrit Shahzad Common Stock 1,289,512 1.5 %
Cuong Do Common Stock 2,671,354 3.1 %
Officers and Directors as a Group (3 persons) Common Stock 10,128,933 11.6 %
Other 5% Shareholders
Elliot Ehrlich Common Stock 7,400,000 8.5 %
Rebecca Guttman Common Stock 8,500,000 9.8 %
RGN Brothers Trust (3) Common Stock 8,500,000 9.8 %
Heard that story about the maytag washer on our Goslings Sunset Rum Cruise. Think they said it is in their museum.
By all means reshare. Just trying to go thru a week worth of emails while very tired.
Yes. Still have them. This is a long term speculative hold. Not concerned with short term fluctuations.
Article online: 15 Distilleries to visit in Kentucky. Jeffersons made the list.
http://vinepair.com/wine-blog/15-distilleries-to-visit-in-kentucky/?utm_source=The+Drop+by+VinePair&utm_campaign=2c7b9030f3-Jun_26_2016&utm_medium=email&utm_term=0_b653fb8c99-2c7b9030f3-45687293
FUN, Just back from Bermuda, having cruised to and from NYC. Saw a few of the racers (Newport to Bermuda) underway and some in port. My pix are from too long a distance, but I may share a few when I get my act together. Meanwhile planning on crashing.
The pix I intend to share are those featuring Goslings. Not great, but taken by me and not publicity shots.
Casker's is pushing Jeff's Ocean Cask Strength again. Must be a popular item there. A bit longer voyage than Trey is taking right now.
Jefferson's Ocean Aged at Sea Cask Strength Kentucky Straight Bourbon Aged at sea on a huge container vessel. this cask strength bourbon stopped in five different continents and crossed the equator four times during its journey.
$149.99 $104.99
The principal author of the Declaration of Independence and one of the greatest Founding Fathers, Thomas Jefferson was elected the third President of the United States in 1800. During his tenure, Jefferson authorized the purchase of the Louisiana Territory, dispatched Lewis and Clark westward in order to explore the remainder of the continent and repealed the Whisky Excise Tax.
After Jefferson retired from public office in 1815, he often tended to the garden that he had cultivated on his Monticello estate. At the time, it was customary for wealthy farmers, including Jefferson, to distill the excess grains they harvested from their farms into spirits (George Washington was one of the country’s largest distillers of rye whiskey). As a result, each farmer’s spirits were unique and reflected the local terrior of their farm. Jefferson’s Ocean Aged At Sea Kentucky Straight Bourbon Whiskey pays homage to Jefferson and the exquisite whiskey he distilled.
Jefferson’s Ocean Aged At Sea Cask Strength Bourbon is first matured in older bourbon casks for approximately six to eight years on land, before the casks are placed on a ship and allowed to rest for another several months at sea. At sea, the bourbon and oak casks are forced to mingle with each other as the ship — which stops in five different continents and crosses the equator four times during the journey — rolls back and forth over the water. In addition, the temperature and barometric pressure fluctuations during the sea voyage cause the oak staves to expand and contract, and allow the bourbon to extract more of the tannins and flavor from the oak during its maturation.
Bottled at cask strength for the first time, Jefferson’s Ocean Aged At Sea Cask Strength Bourbon has an aroma of cinnamon buns, orange zest, burnt sugar and marshmallow. Thick notes of salted caramel, figs and chocolate fudge dominate the palate, and lead to a playful finish accented by sweet mint, lemon cake and nutmeg.
We have only a handful of bottles available. Pick up a bottle today!
Wild, Thank you for sending that.
LR, Dun & Bradstreet rates private businesses, like Aspire Capital.
loanranger Member Level Thursday, 06/16/16 07:02:44 PM
Re: Rdunn88 post# 151817
Post # of 151843
"Does anyone know if they're even rated? "
Who rates private investment companies?
I do not think the new rules for compassionate use are in effect yet. Best bet is to call CTSO and ask. ASAP
BTW, just ran across this article on stocks which have done well after a r/s. I was in Inovio at the time and still hold my shares.
My gut tells me that more companies suffer from a r/s than benefit by one. Of course, that includes many companies which are already in extremis and trying to keep from going under. Also includes pump and dump operations which dilute existing shareholders, issue more shares to themselves, sell those and repeat the cycle. I would not put COCP in this category.
http://news.investornetwork.com/2016/06/14/these-companies-prove-that-reverse-splits-can-be-a-very-good-thing-for-stakeholders/?1=1&1465936593
The article was put out by a company which promotes other companies by putting out PR pieces. Hence not exactly unbiased. You should read the disclaimer at the end.